Scientific publications

Increased levels of calprotectin in obesity are related to macrophage content. Impact on inflammation and effect of weight loss

Catalán V, Gómez-Ambrosi J [SP], Rodríguez A, Ramírez B, Rotellar F, Valentí V, Silva C [SP], Gil MJ [SP], Fernández-Real JM, Salvador J, Frühbeck G [SP].
Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Spain

Magazine: Molecular Medicine

Date: Jul 5, 2011

General and Digestive Surgery Biochemistry [SP] Endocrinology and Nutrition [SP] Obesity Unit

Calprotectin has been recently described as a novel marker of obesity.

The aim was to determine the circulating concentrations and expression levels of calprotectin subunits (S100A8 and S100A9) in VAT exploring its impact on insulin resistance and inflammation and the effect of weight loss.

We included 53 subjects in the study. Gene expression levels of S100A8/A9 complex were analyzed in VAT as well as in both adipocytes and SVFC.

In addition, circulating calprotectin and sRAGE concentrations were measured before and after weight loss achieved by Roux-en-Y gastric bypass (RYGB) (n=26). Circulating concentrations and VAT expression of S100A8/A9 complex were increased in normoglycemic and type 2 diabetic obese patients (P<0.01) and associated with markers of inflammation (P<0.01). Oppositely, concentrations of sRAGE were significantly lower (P<0.001) in both obese groups compared to lean volunteers. Elevated calprotectin levels in obese patients decreased (P<0.00001) after RYGB while sRAGE concentrations tended to increase. Calprotectin was mainly expressed by SVFC and its expression was significantly correlated (P<0.01) with mRNA levels of the monocyte-macrophage-related molecules CD68, MCP1, CD11B and NOX2. TNF-? treatment significantly enhanced (P<0.05) the mRNA levels of S100A8 of human visceral adipocytes.

The increased levels of calprotectin in obesity and obesity-associated T2D, its positive association with inflammation as well as the higher expression levels in the SVFC in VAT suggests a potential role of this protein as a chemotactic factor in the recruitment of macrophages to VAT increasing inflammation and the development of obesity-associated comorbidities.

CITATION  Mol Med. 2011 Jul 5. doi: 10.2119/molmed.2011.00144

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra